Roche Holding AG (OTCMKTS:RHHVF – Get Rating) has been assigned a consensus recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $416.00.
Separately, Stifel Nicolaus assumed coverage on shares of Roche in a research report on Monday, February 28th. They issued a “buy” rating and a $410.00 target price for the company.
Shares of OTCMKTS:RHHVF traded up $10.29 on Friday, hitting $326.30. The company had a trading volume of 969 shares, compared to its average volume of 8,324. The firm’s 50-day simple moving average is $378.74 and its two-hundred day simple moving average is $386.62. Roche has a 1 year low of $313.84 and a 1 year high of $430.00.
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
- Get a free copy of the StockNews.com research report on Roche (RHHVF)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.